Hong Kong market could open cash flood gates for U.S. biotechs

(Reuters) - When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news